Randomized, Multi-Center, Double Blind Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer
Sponsor: AstraZeneca
Participating sites:
- UZ Leuven, Leuven
- UZ Gent, Gent
- CHU UCL St-Luc, Bruxelles
- Hôpital de Libramont, Libramont
- AZ Groeninge, Kortrijk
- AZ Sint Jan Brugge, Brugge
- Grand Hôpital de Charleroi, Charleroi
- Clinique CHC Montlégia, Liège
- Jessa Ziekenhuis, Hasselt